AGEN Stock Overview
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.
Agenus Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.56|
|52 Week High||US$3.62|
|52 Week Low||US$1.25|
|1 Month Change||4.92%|
|3 Month Change||0.79%|
|1 Year Change||-20.74%|
|3 Year Change||-35.19%|
|5 Year Change||-24.04%|
|Change since IPO||-99.30%|
Recent News & Updates
Auditors Have Doubts About Agenus (NASDAQ:AGEN)Mar 06
Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings ForecastsAug 11
Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?Feb 15
What Type Of Returns Would Agenus'(NASDAQ:AGEN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Dec 24
|AGEN||US Biotechs||US Market|
Return vs Industry: AGEN underperformed the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: AGEN underperformed the US Market which returned -17.6% over the past year.
|AGEN Average Weekly Movement||13.8%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: AGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: AGEN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
|AGEN fundamental statistics|
Is AGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGEN income statement (TTM)|
|Cost of Revenue||US$190.65m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.70|
|Net Profit Margin||-238.83%|
How did AGEN perform over the long term?See historical performance and comparison